* the truisms are that most men die with rather than of prostate cancer, if you live long enough almost all men will get a couple of cancer cells in the prostate
Dr. Matthew Cooperberg takes us on a candid journey through Active Surveillance for prostate cancer—starting with its earliest days in the 1990s, through the ups and downs of PSA screening and treatment trends, and into today’s era of MRI, genomic tests, and AI-guided risk assessment.
This presentation is particularly exceptional, delivered as Dr. Cooperberg...
* For clinicians considering TTh in men after prostate cancer treatment, several considerations should guide decision-making. Patient selection is critical with regular monitoring, with close attention to PSA velocity and testosterone levels. The benefits of treating hypogonadism, including improvements in energy, sexual function, bone density, body composition, and potentially cardiovascular health, must be weighed against the theoretical risk of promoting occult cancer cells in each individual patient. The current literature suggests that TTh can be safely...